medicineThe Big StoryPsychedelic Therapy Crashed and Burned. MAHA Might Bring It BackBy John SemleyPoliticsAn Inventor Is Injecting Bleach Into Cancerous Tumors—and Wants to Bring the Treatment to the USBy David GilbertScienceWho Controls Your Health? Test Your Knowledge of the MAHA MovementBy Elana KleinThe Big StoryThe Next Thing You Smell Could Ruin Your LifeBy Lexi PandellThe Big StoryDoes Anyone Know What ‘Wellness’ Means Anymore?By Katie DrummondScienceHow Trump Killed Cancer ResearchBy Elisa Muyl and Anthony LydgateScienceDr. ChatGPT Will See You NowBy Ryan FlinnBusinessMicrosoft Says Its New AI System Diagnosed Patients 4 Times More Accurately Than Human DoctorsBy Will KnightCultureSnake Venom, Urine, and a Quest to Live Forever: Inside a Biohacking Conference Emboldened by MAHABy Will BahrScienceEli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1sBy Emily MullinBusinessThose Creatine Gummies You Bought Online Might Not Contain Any CreatineBy Kate KnibbsScienceScientists Discover the Key to Axolotls’ Ability to Regenerate LimbsBy Anna LagosCultureThis Historian Has Seen the Future of Trans Health CareBy Harron WalkerStartups‘Uber for Getting Off Antidepressants’ Launches in the USBy Kate KnibbsPoliticsThe Bleach Community Is Ready for RFK Jr. to Make Their Dreams Come TrueBy David GilbertGearWhat Are Exosomes, and Why Are They in Your Skin Care?By Boutayna Chokrane ScienceWhy Women With Type 2 Diabetes Are Diagnosed Later Than MenBy Lori YoumshajekianScienceA Baby Received a Custom Crispr Treatment in Record TimeBy Emily MullinBusinessBlocked From Selling Off-Brand Ozempic, Telehealth Startups Embrace a Less Effective DrugBy Kate KnibbsSciencePatients Are Left With Few Options as GLP-1 Copycats DisappearBy Emily Mullin and Kate KnibbsScienceDiabetes Is Rising in Africa. Could It Lead to New Breakthroughs?By David CoxBusinessOpenAI and the FDA Are Holding Talks About Using AI In Drug EvaluationBy Zoë Schiffer, Emily Mullin, and Will KnightScienceHHS Orders Lab Studying Deadly Infectious Diseases to Stop ResearchBy Emily MullinBusinessEli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff DrugsBy Kate Knibbs and Emily MullinMore Stories
